<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><description>传递医药信息，分享资源数据！充电5分钟，吹牛2小时！</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 26 Apr 2021 19:22:53 +0800</pubDate><image><url>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</url><title>医药魔方Info | wechat-feeds</title><link>http://MzU2MTcxOTAwMw.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>全球首个CD38单抗新适应症即将在华获批，2020年销售额41.9亿美元</title><link>https://mp.weixin.qq.com/s/ENd_IZi2B7XvfVnl3pkRDg</link><description></description><content:encoded><![CDATA[全球首个CD38单抗新适应症即将在华获批，2020年销售额41.9亿美元]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>医药魔方征稿 | 分享真知灼见，碰撞思维火花！</title><link>https://mp.weixin.qq.com/s/BFxI6mHdYVj71kFkUIrh6A</link><description></description><content:encoded><![CDATA[医药魔方征稿 | 分享真知灼见，碰撞思维火花！]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>魔方研报分享 | 2020中国医药市场回顾—销售市场篇</title><link>https://mp.weixin.qq.com/s/wVxum9BDzbR0R1vca59DxQ</link><description></description><content:encoded><![CDATA[魔方研报分享 | 2020中国医药市场回顾—销售市场篇]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>罗氏PD-L1第3项适应症即将获批！一线治疗NSCLC</title><link>https://mp.weixin.qq.com/s/cd8AsntNVlupMnAqc5cFPQ</link><description></description><content:encoded><![CDATA[罗氏PD-L1第3项适应症即将获批！一线治疗NSCLC]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>今日，12款仿制药通过一致性评价，5款为首家</title><link>https://mp.weixin.qq.com/s/S_bPcFpSSz3T55onQflqDA</link><description></description><content:encoded><![CDATA[今日，12款仿制药通过一致性评价，5款为首家]]></content:encoded><pubDate>Mon, 26 Apr 2021 18:32:29 +0800</pubDate></item><item><title>优效于阿普斯特！百时美施贵宝first-in-class 口服TYK-2抑制剂两项III期研究结果公布（附PPT）</title><link>https://mp.weixin.qq.com/s/lY-v1E2aZ1CePAAIMbmKjA</link><description></description><content:encoded><![CDATA[优效于阿普斯特！百时美施贵宝first-in-class 口服TYK-2抑制剂两项III期研究结果公布（附PPT）]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>博安生物在《Nature》杂志子刊发表新冠中和抗体研究成果</title><link>https://mp.weixin.qq.com/s/wS6YjNEv-JI74X9LEH5vaw</link><description></description><content:encoded><![CDATA[博安生物在《Nature》杂志子刊发表新冠中和抗体研究成果]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>直播预告 | 2021年3月全球新药研发进展</title><link>https://mp.weixin.qq.com/s/5Eay5koAA1MZLRZ3UnG2tw</link><description></description><content:encoded><![CDATA[直播预告 | 2021年3月全球新药研发进展]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>魔方研报分享 | 2020中国医药市场回顾—重磅政策分析篇</title><link>https://mp.weixin.qq.com/s/wX-MAq4l45GK-0zolryV9Q</link><description></description><content:encoded><![CDATA[魔方研报分享 | 2020中国医药市场回顾—重磅政策分析篇]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>罗氏2021第1季度业绩：总收入149.3 亿瑞士法郎，新产品持续发力，占制药业务50%</title><link>https://mp.weixin.qq.com/s/cQjb9IJfo-FAhQpx1AylHg</link><description></description><content:encoded><![CDATA[罗氏2021第1季度业绩：总收入149.3 亿瑞士法郎，新产品持续发力，占制药业务50%]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>20年来首个全新机制抗流感新药！罗氏Xofluza即将获批上市</title><link>https://mp.weixin.qq.com/s/2piuZojxSukm14M5V2CX6g</link><description></description><content:encoded><![CDATA[20年来首个全新机制抗流感新药！罗氏Xofluza即将获批上市]]></content:encoded><pubDate>Sun, 25 Apr 2021 18:38:16 +0800</pubDate></item><item><title>首款CD19 ADC获FDA批准上市</title><link>https://mp.weixin.qq.com/s/ZgUWPacvPhl-9ynKIEfemQ</link><description></description><content:encoded><![CDATA[首款CD19 ADC获FDA批准上市]]></content:encoded><pubDate>Sat, 24 Apr 2021 10:27:28 +0800</pubDate></item><item><title>首仿！豪森戒烟药「酒石酸伐尼克兰片」获批上市</title><link>https://mp.weixin.qq.com/s/dg8s_OzzIg6G_jurgv_aig</link><description></description><content:encoded><![CDATA[首仿！豪森戒烟药「酒石酸伐尼克兰片」获批上市]]></content:encoded><pubDate>Sat, 24 Apr 2021 10:27:28 +0800</pubDate></item><item><title>华领医药first in class降糖药申报上市</title><link>https://mp.weixin.qq.com/s/97fVfaktwfAeK4vlRWn4Gw</link><description></description><content:encoded><![CDATA[华领医药first in class降糖药申报上市]]></content:encoded><pubDate>Fri, 23 Apr 2021 18:54:02 +0800</pubDate></item><item><title>葛兰素史克PD-1抗体获FDA加速批准上市</title><link>https://mp.weixin.qq.com/s/Of_Gjq_r7s0YZOwC2bJNcA</link><description></description><content:encoded><![CDATA[葛兰素史克PD-1抗体获FDA加速批准上市]]></content:encoded><pubDate>Fri, 23 Apr 2021 18:54:02 +0800</pubDate></item><item><title>持续加码糖尿病领域！通化东宝首个三靶点糖尿病新药申报临床</title><link>https://mp.weixin.qq.com/s/pm29eaNGgZTcWdpExMcsmw</link><description></description><content:encoded><![CDATA[持续加码糖尿病领域！通化东宝首个三靶点糖尿病新药申报临床]]></content:encoded><pubDate>Fri, 23 Apr 2021 18:54:02 +0800</pubDate></item><item><title>特瑞普利单抗一线治疗食管鳞癌III期研究成功</title><link>https://mp.weixin.qq.com/s/Ps3UI286HGOSqUfDLvZuag</link><description></description><content:encoded><![CDATA[特瑞普利单抗一线治疗食管鳞癌III期研究成功]]></content:encoded><pubDate>Fri, 23 Apr 2021 18:54:02 +0800</pubDate></item><item><title>美诺华与全球医药巨头默沙东达成十年战略合作</title><link>https://mp.weixin.qq.com/s/a7M-o2JnGlDRotKWl6aoQA</link><description></description><content:encoded><![CDATA[美诺华与全球医药巨头默沙东达成十年战略合作]]></content:encoded><pubDate>Thu, 22 Apr 2021 18:16:52 +0800</pubDate></item><item><title>首仿！豪森戒烟药「酒石酸伐尼克兰片」即将获批上市</title><link>https://mp.weixin.qq.com/s/HgxiVjnr_FythoZMrqE0AQ</link><description></description><content:encoded><![CDATA[首仿！豪森戒烟药「酒石酸伐尼克兰片」即将获批上市]]></content:encoded><pubDate>Thu, 22 Apr 2021 18:16:52 +0800</pubDate></item><item><title>罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟</title><link>https://mp.weixin.qq.com/s/SNXnKr88EnhXmObmS3uNIg</link><description></description><content:encoded><![CDATA[罗氏曲妥珠单抗皮下注射液申报上市，给药时间仅需2-5分钟]]></content:encoded><pubDate>Thu, 22 Apr 2021 18:16:52 +0800</pubDate></item></channel></rss>